The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis
This study has been completed.
Sponsor:
Samsung Medical Center
Information provided by:
Samsung Medical Center
ClinicalTrials.gov Identifier:
NCT01171768
First received: July 16, 2010
Last updated: July 20, 2011
Last verified: July 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) are major mediators of angiogenesis and are induced by tissue inflammation and hypoxia. While elevated serum VEGF levels have been reported in inflammatory lung diseases, especially with hemoptysis, there was no study to evaluate the Ang-2 levels in lung inflammatory diseases according to the presence of hemoptysis, inflammatory biomarker and hypoxia.
| Condition |
|---|
|
Inflammatory Lung Diseases Hemoptysis |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis |
Further study details as provided by Samsung Medical Center:
Primary Outcome Measures:
- serum VEGF and Ang-2 level in lung inflammatory disease according to the presence of hemoptysis [ Time Frame: up to 7 days after enrollment ] [ Designated as safety issue: Yes ]We'll measure the serum VEFG and Ang-2 level of enrolled patients within a week from the moment that patients agree to enroll this study. Therefore, Comparison of the serum VEGF and Ang-2 level (measured within a week from enrollment) according to the presence of hemoptysis will be primary outcome.
Secondary Outcome Measures:
- to investigate association between angiogenesis factors and other factors such as inflammatory biomarker and hypoxia. [ Time Frame: up to 7 days after enrollment ] [ Designated as safety issue: Yes ]We'll measure the serum VEFG, Ang-2 level, and other factors such as inflammatory biomarkers and PaO2 of enrolled patients within a week from the moment that patients agree to enroll this study. Therefore, Investigating association between angiogensis factors and other factors such as inflammatory biomarker and hypoxia, which were measured within a week from enrollment, will be secondary outcome.
| Estimated Enrollment: | 52 |
| Study Start Date: | June 2008 |
| Study Completion Date: | December 2010 |
| Groups/Cohorts |
|---|
| patients with hemoptysis within 2 weeks |
| patients without hemoptysis within 2 years |
Eligibility| Ages Eligible for Study: | 20 Years to 90 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
patients visited Samsung Medical Center for the treatment of benign inflammatory disease such as bronchiectasis, aspergilloma, peumonia and post-tuberculosis destroyed lung
Criteria
Inclusion Criteria:
- patients visited Samsung Medical Center for the treatment of benign inflammatory disease such as bronchiectasis, aspergilloma, pneumonia and post-tuberculosis destroyed lung
Exclusion Criteria:
- patients with tumorous condition including lung cancer, vasculitis and the lung disease associated with collagen vascular disease on the point of enrollment
Contacts and Locations More Information
No publications provided
| Responsible Party: | Sang-Won Um, Samsung Medical Center |
| ClinicalTrials.gov Identifier: | NCT01171768 History of Changes |
| Other Study ID Numbers: | 2008-05-043 |
| Study First Received: | July 16, 2010 |
| Last Updated: | July 20, 2011 |
| Health Authority: | Korea: Institutional Review Board |
Keywords provided by Samsung Medical Center:
|
Vascular endothelial growth factor angiopoietin-2 |
Additional relevant MeSH terms:
|
Hemoptysis Lung Diseases Respiratory Tract Diseases Hemorrhage |
Pathologic Processes Signs and Symptoms, Respiratory Signs and Symptoms |
ClinicalTrials.gov processed this record on May 23, 2013